In Phase C, members will acquire ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Members will get treatment until finally disorder progression or maybe the members are not able to tolerate the study drugs. and then promote H3K27Ac at this location. Chromatin hyperacetylation could enhance https://abbv-744preclinicalstudie04669.frewwebs.com/32524851/detailed-notes-on-abbv-744-brd4-inhibitor-mechanism-of-action